IQVIA Institute

279 data points extracted from 9 publications by this organisation.

Data points
279
Documents
9
Indicators
174
Regions
5
Publisher type
Research

Bibliography

Documents used

Every publication we have taken a number from, with the date we read it and the link status at that time.

Document Type Published Retrieved Link Data points
Global R&D Trends 2026 Licence: See source Press release 15 Sep 2026 Reachable 35
Supporting patients through research collaboration Licence: See source Press release 16 Sep 2026 Reachable 10
Global Oncology Trends 2025 Licence: See source Press release 16 Sep 2026 Reachable 57
U.S. Medicine Use Trends 2026 Licence: See source Press release 15 Sep 2026 Reachable 56
Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios Licence: See source Press release 15 Sep 2026 Reachable 22
Global R&D Trends 2026 Licence: See source Press release 15 Sep 2026 Reachable 35
Rethinking Clinical Trial Country Prioritization Licence: See source Press release 15 Sep 2026 Reachable 33
Global Medicine Use Trends 2026 Licence: See source Press release 15 Sep 2026 Reachable 30
IQVIA Institute’s Global R&D Trends 2026 Report Finds Credible Signal on AI-Enabled Programs Licence: See source Press release 17 Sep 2026 Reachable 1

Every figure

Data points

Every figure taken from this organisation, grouped by indicator.

279 data points across 174 indicators.
IndicatorRegionPeriodValueTypeFull record
Additional novel active substance launchesGlobal2026–2030375forecast
Aggregate revenue of patient organizationsUnited States2016–202062.5 billion USDactual
Annual revenue growth rate of largest patient organizationsUnited States2016–20205%actual
Average annual growth in cancer medicine spendingGlobal2020–202411.9%actual
Average annual novel active substance launchesGlobal2026–203075forecast
Average annual oncology novel active substance launches (multi-year total)Global2020–202426actual
Average annual oncology novel active substance launches (multi-year total)Global2015–201916actual
Average annual revenue of patient organizationsUnited States2016–202012.5 billion USDestimate
Cancer medicine spendingGlobal2029441 billion USDforecast
Cancer medicine spendingGlobal2024252 billion USDactual
Cell and gene therapy clinical trial startsGlobal2023631actual
Cell and gene therapy clinical trial startsGlobal2019–20233,285actual
Cell and gene therapy cumulative launchesGlobalend of 202376actual
Cell and gene therapy reimbursement rateEuropean Unionas of 1 Apr 202342%actual
Cell and gene therapy reimbursement rateEuropean UnionApril 202342%actual
Cell and gene therapy share of medicine spendingGlobal20230.4%actual
Cell and gene therapy spendingGlobal20235.9 billion USDactual
Cell and gene therapy spending average annual growth rateGlobal2019–202365%actual
Cell and gene therapy spending growth rateGlobal202338%actual
Cell and gene therapy spending share by geographyGlobal202338%actual
Cell and gene therapy spending share by geographyUnited States202362%actual
Cell and gene therapy spending year-over-year growthGlobal202338%actual
Cell and gene therapy venture capital and public funding deal countGlobal2023100estimate
Cell and gene therapy venture capital and public funding deal countGlobal202396actual
Cell and gene therapy venture capital and public funding deal countGlobal202297actual
Cell and gene therapy venture capital and public funding deal countGlobal2021127actual
Cell and gene therapy venture capital and public funding deal valueGlobal20233.4 billion USDactual
Cell and gene therapy venture funding deal count year-over-year changeGlobal202319%actual
Cell and gene therapy venture funding deal count year-over-year changeGlobal2022-24%actual
Cell and gene therapy venture funding deal count year-over-year changeGlobal202157%actual
Change in regional share of global clinical trial country usesEuropean Union2019–2025-17%actual
Change in regional share of global clinical trial country usesEuropean Union2019–2025-17%actual
Change in regional share of global clinical trial country usesEuropean Union2019–202321%actual
Change in regional share of global clinical trial country usesNorth America2019–202317%actual
Change in regional share of global clinical trial country usesChina2019–202357%actual
Clinical trial country use shareEuropean Union202527%actual
Clinical trial country use shareEuropean Union202527%actual
Clinical trial country use shareEuropean Union202325%actual
Clinical trial country use shareNorth America202323%actual
Clinical trial country use shareChina202315%actual
Clinical trial country use shareChina2021–202313%actual
Clinical trial country use shareUnited States2021–202316%actual
Clinical trial country use shareEuropean Union201932%actual
Clinical trial country use shareNorth America201919%actual
Clinical trial country use shareChina201910%actual
Clinical trial country use share changeEuropean Union2019–2023-21%actual
Clinical trial country use share changeNorth America2019–202317%actual
Clinical trial country use share changeChina2019–202357%actual
Clinical trial country uses growth rateEuropean Union2019–2025-17%actual
Clinical trial country utilization growth rateEuropean Union2019–2025-17%actual
Clinical trial enrollment duration growthGlobal2019–202326%actual
Clinical trial enrollment duration increaseGlobal2019–202326%actual
Clinical trial enrollment duration increase (multi-year total)Global2019–20236 monthsactual
Commercial insurance out-of-pocket cost growthUnited States20255%actual
Commercial insurance out-of-pocket cost growth (5-year)United States2021–202537%actual
Commercial insurance patient out-of-pocket medicine cost growth rateUnited States20255%actual
Commercial insurance share of patient out-of-pocket costsUnited States202552%actual
Commercial insurance share of patient out-of-pocket medicine costsUnited States202552%actual
Compound annual net medicine spending growthUnited States2020–20259.3%actual
Countries (excluding U.S.) driving global pharmaceutical spending growthGlobal2025–203014forecast
Country share of clinical trial country-usesChina2021–202313%actual
Country share of clinical trial country-usesUnited States2021–202316%actual
COVID-19 vaccines and therapeutics spending declineUnited States20254 billion USDactual
Cumulative cell and gene therapy launchesGlobalend of 202376actual
Cumulative five-year novel active substance launchesGlobal2021–2025388actual
Cumulative five-year novel active substance launchesGlobal2021–2025388actual
Cumulative five-year novel active substance launchesUnited States2021–2025270actual
Cumulative five-year novel active substance launchesUnited States2021–2025270actual
Cumulative five-year novel active substance launches excluding COVID-19 vaccines and therapeuticsGlobal2021–2025369actual
Cumulative oncology novel active substance launchesGlobal2020–2024132actual
Cumulative oncology novel active substance launchesGlobal2015–201979actual
Cumulative oncology novel active substance launchesGlobal2005–2024282actual
Domestic-only oncology NAS launches (cumulative)China2020–202445actual
Domestic-only oncology novel active substance launches (multi-year total)China2020–202445actual
Expected annual novel active substance launches (lower bound)Global2026–203070forecast
Expected annual novel active substance launches (lower bound)United States2026–203050forecast
Expected annual novel active substance launches (upper bound)Global2026–203080forecast
Expected annual novel active substance launches (upper bound)United States2026–203055forecast
Expected cumulative novel active substance launches (lower bound)Global2026–2030350forecast
Expected cumulative novel active substance launches (upper bound)Global2026–2030400forecast
Fill rate for novel medicine prescriptions (first year)United States2020–202435%actual
First-in-class novel active substance launchesGlobal202530actual
First-in-class novel active substance launchesGlobal202530actual
First-year new prescriptions for novel medicines (multi-year total)United States2020–20247 millionactual
Five-year cumulative medicine use growthUnited States2020–202513%actual
Five-year cumulative novel active substance launches excluding COVID-19Global2021–2025369actual
Forecast list-price medicine spending growth lower boundUnited States2026–20306%forecast
Forecast list-price medicine spending growth upper boundUnited States2026–20309%forecast
Forecast net medicine spending growth lower boundUnited States2026–20304.5%forecast
Forecast net medicine spending growth upper boundUnited States2026–20307.5%forecast
GIP/GLP-1 agonist spending growth contributionUnited States202514 billion USDactual
Growth in cancer medicine spendingGlobal2019–202475%actual
High GDP developed countries medicine spending growthGlobal2025–2030155.1 billion USDforecast
Inter-trial interval increaseGlobal20253 monthsactual
Large company small molecule share of Phase I clinical trial startsGlobal202566%actual
Large company small molecule share of Phase I clinical trial startsGlobal202566%actual
Large company small molecule share of Phase I clinical trial startsGlobal202261%actual
Large company small molecule share of Phase I clinical trial startsGlobal202261%actual
Life sciences and patient organization deal valueUnited Statesas of 5 Oct 20232.4 billion USDestimate
Life sciences and patient organization dealsUnited Statesas of 5 Oct 2023700estimate
Medicare out-of-pocket cost decline rateUnited States20252.2%actual
Medicare out-of-pocket cost increase rate versus 2020United States2020–202523%actual
Medicare patient out-of-pocket medicine cost declineUnited States2025638 million USDactual
Medicare patient out-of-pocket medicine cost decline rateUnited States20252.2%actual
Medicine market average annual growth at net prices (5-year)United States2021–20259.3%actual
Medicine spendingGlobal20302.6 trillion USDforecast
Medicine spendingGlobal20231.6 trillion USDactual
Medicine spending growth forecast at list prices (high)United States2026–20309%forecast
Medicine spending growth forecast at list prices (low)United States2026–20306%forecast
Medicine spending growth forecast at net prices (high)United States2026–20307.5%forecast
Medicine spending growth forecast at net prices (low)United States2026–20304.5%forecast
Medicine spending growth rate forecast (annual, high estimate)Global2025–20308%forecast
Medicine spending growth rate forecast (annual, low estimate)Global2025–20305%forecast
Medicine spending growth rate lower boundGlobal2026–20305%forecast
Medicine spending growth rate upper boundGlobal2026–20308%forecast
Medicine usage indexChinaend of 2030196forecast
Medicine usage indexChina2030196forecast
Medicine use compound annual growth rateGlobal2026–20302.7%forecast
Medicine use compound annual growth rateGlobal2025–20302.7%forecast
Medicine use growth rateGlobal2025–20302.7%forecast
Medicine use index (2020=100)China2030196 indexforecast
Medicine use index (2020=100)China2020100 indexactual
Medicine use volumeGlobal20304 trillion defined daily dosesforecast
Multi-country oncology clinical trial startsGlobal2024403actual
Multi-country oncology clinical trial startsGlobal2021644actual
Multi-country oncology clinical trial startsGlobal2015503actual
Multi-country oncology trial shareGlobal202420%actual
Multi-country oncology trial shareGlobal201537%actual
Multi-country oncology trial startsGlobal2024403actual
Multi-country oncology trial startsGlobal2021644actual
Multi-country oncology trial startsGlobal2015503actual
Multi-country share of oncology clinical trial startsGlobal202420%actual
Multi-country share of oncology clinical trial startsGlobal201537%actual
Net medicine spendingUnited States2025606 billion USDactual
Net medicine spendingUnited States2024548 billion USDactual
Net medicine spending growthUnited States202510.6%actual
Net medicine spending growth rateUnited States202510.6%actual
Net medicine spending growth rateUnited States2024–202510.6%actual
Net medicine spending increaseUnited States202558 billion USDactual
New medicine launches forecast (annual average, high)United States2026–203055forecast
New medicine launches forecast (annual average, low)United States2026–203050forecast
Non-retail share of medicine useUnited States202516%actual
Non-retail share of prescription medicine useUnited States202516%actual
Novel active substance launchesGlobal202579actual
Novel active substance launchesGlobal202579actual
Novel active substance launchesGlobal202579actual
Novel active substance launchesUnited States202553actual
Novel active substance launchesUnited States202553actual
Novel active substance launches (multi-year total)United States2021–2025270actual
Novel active substance launches (multi-year total)United States2020–202499actual
Novel active substance launches growth rateUnited States2021–202517%actual
Novel active substance launches growth rateUnited States2021–202517%actual
Novel active substance launches, five-year totalGlobal2021–2025388actual
Novel active substance launches, five-year totalGlobal2021–2025388actual
Novel active substance launches, five-year totalUnited States2021–2025270actual
Novel active substance launches, five-year totalUnited States2021–2025270actual
Novel active substance launches, five-year total (excluding COVID-19 products)Global2021–2025369actual
Novel active substance launches, five-year total (excluding COVID-19 products)Global2021–2025369actual
Novel active substance launches, forecast annual averageGlobal2026–203075forecast
Novel active substance launches, forecast annual averageGlobal2026–203075forecast
Novel active substance launches, forecast five-year growthGlobal2026–2030375forecast
Novel active substance launches, forecast five-year growthGlobal2026–2030375forecast
Novel active substances launched exclusively in ChinaChina202530actual
Novel active substances launched exclusively in ChinaChina202530actual
Novel medicine prescription fill rateUnited States2020–202435%actual
Novel medicine prescription patient abandonment rateUnited States2020–202417%actual
Novel medicine prescription payer rejection rateUnited States2020–202449%actual
Novel medicine prescription unfilled rateUnited States2020–202465%actual
Novel medicines launchedUnited States2020–202499actual
Novel modalities share of oncology clinical trialsGlobal202435%actual
Novel modality share of oncology trialsGlobal202435%actual
Obesity-approved GIP and GLP-1 agonist medicine spending growthUnited States20259.6 billion USDactual
Oncology clinical development productivity growthGlobal2019–202451%actual
Oncology clinical development productivity improvementGlobal2019–202451%actual
Oncology clinical trial startsGlobal20242,162actual
Oncology clinical trial starts growth rateGlobal2024–2025-4%actual
Oncology clinical trial starts growth rateGlobal2024–2025-4%actual
Oncology clinical trial starts growth rateGlobal2019–202412%actual
Oncology clinical trial starts growth rateGlobal2014–202458%actual
Oncology medicine spending at list pricesGlobal2029441 billion USDforecast
Oncology medicine spending at list pricesGlobal2024252 billion USDactual
Oncology medicine spending growth (5-year)Global2019–202475%actual
Oncology medicine spending growth (annualized)Global2020–202411.9%actual
Oncology novel active substance (NAS) launches (annual)Global202425actual
Oncology novel active substance (NAS) launches (annual)Global2020–202426actual
Oncology novel active substance (NAS) launches (annual)Global2015–201916actual
Oncology novel active substance (NAS) launches (cumulative)Global2020–2024132actual
Oncology novel active substance (NAS) launches (cumulative)China2020–202484actual
Oncology novel active substance (NAS) launches (cumulative)United States2020–202485actual
Oncology novel active substance (NAS) launches (cumulative)Global2015–201979actual
Oncology novel active substance (NAS) launches (cumulative)China2015–201937actual
Oncology novel active substance (NAS) launches (cumulative)Global2005–2024282actual
Oncology novel active substance launchesGlobal202425actual
Oncology novel active substance launches (multi-year total)China2020–202484actual
Oncology novel active substance launches (multi-year total)United States2020–202485actual
Oncology novel active substance launches (multi-year total)China2015–201937actual
Oncology share of all clinical trialsGlobal202441%actual
Oncology trial starts growth over last decadeGlobal2014–202458%actual
Oncology trial starts growth vs 2019Global2019–202412%actual
Oncology trials share of all clinical trialsGlobal202441%actual
Patient organization donor share in life sciences dealsGlobalas of 5 Oct 202375%actual
Patient organization input share in drug health technology assessmentsGlobalas of 5 Oct 202321%actual
Patient organization input share in drug health technology assessmentsEuropean Unionas of 5 Oct 202352%actual
Patient organization-life sciences company deal valueUnited States2008–20232.4 billion USDestimate
Patient organization-life sciences company dealsUnited States2008–2023700estimate
Patient out-of-pocket medicine cost increaseUnited States20256 billion USDactual
Patient out-of-pocket medicine costsUnited States2025110 billion USDactual
Per capita medicine use compound annual growth rateGlobal2026–20301.9%forecast
Per capita medicine use compound annual growth rateNorth America2026–20300.9%forecast
Per capita medicine use compound annual growth rateGlobal2025–20301.9%forecast
Per capita medicine use compound annual growth rateNorth America2025–20300.9%forecast
Per capita medicine use compound annual growth rateNorth America2020–20252.1%actual
Per capita medicine use growth rateGlobal2025–20301.9%forecast
Per capita medicine use growth rateNorth America2025–20300.9%forecast
Per capita medicine use growth rateNorth America2020–20252.1%actual
Pharmerging markets medicine spending growthGlobal2026–2030121 billion USDforecast
Pharmerging markets medicine spending growthGlobal2025–2030121 billion USDforecast
Pharmerging markets medicine spending growthGlobal2020–2025118 billion USDactual
Phase I clinical trial enrollment duration increaseGlobal2019–202339%actual
Phase I clinical trial enrollment duration increase (months)Global2019–20235 monthsactual
Phase I immunology clinical trial starts growth rateGlobal2024–2025-13%actual
Phase I immunology clinical trial starts growth rateGlobal2024–2025-13%actual
Phase I share of oncology clinical trial startsGlobal202438%actual
Phase I share of oncology trialsGlobal202438%actual
Phase I small molecule clinical trial shareGlobal202562%actual
Phase I small molecule clinical trial shareGlobal202562%actual
Phase I small molecule clinical trial shareGlobal202360%actual
Phase I small molecule clinical trial shareGlobal202360%actual
Phase I small molecule clinical trial shareGlobal201672%actual
Phase I small molecule clinical trial shareGlobal201672%actual
Phase II clinical trial enrollment duration increaseGlobal2019–202323%actual
Phase II clinical trial enrollment duration increase (months)Global2019–20236 monthsactual
Phase II immunology clinical trial starts growth rateGlobal2024–202514%actual
Phase II immunology clinical trial starts growth rateGlobal2024–202514%actual
Phase II oncology clinical trial starts growth rateGlobal2024–20253%actual
Phase II oncology clinical trial starts growth rateGlobal2024–20253%actual
Phase II share of oncology clinical trial startsGlobal202448%actual
Phase II share of oncology trialsGlobal202448%actual
Phase III clinical trial enrollment duration increaseGlobal2019–202316%actual
Phase III immunology clinical trial starts growth rateGlobal2024–2025-4%actual
Phase III immunology clinical trial starts growth rateGlobal2024–2025-4%actual
Phase III oncology clinical trial starts growth rateGlobal2024–20254%actual
Phase III oncology clinical trial starts growth rateGlobal2024–20254%actual
Phase III share of oncology clinical trial startsGlobal202414%actual
Phase III share of oncology trialsGlobal202414%actual
Prescription medicine useUnited States2025210 billion days of therapyactual
Prescription medicine use growthUnited States20251.5%actual
Prescription medicine use growth (5-year)United States2021–202513%actual
Projected net medicine spending increaseUnited States2025–2030200 billion USDforecast
Rare cancer share of oncology clinical trial startsGlobal202474%actual
Rare cancer share of oncology trial startsGlobal202474%actual
Regional share of global clinical trial country usesEuropean Unionend of 202325%actual
Regional share of global clinical trial country usesNorth Americaend of 202323%actual
Regional share of global clinical trial country usesChinaend of 202315%actual
Regional share of global clinical trial country usesEuropean Unionend of 201932%actual
Regional share of global clinical trial country usesNorth Americaend of 201919%actual
Regional share of global clinical trial country usesChinaend of 201910%actual
Regional share of global clinical trial country uses (annual)European Union202527%actual
Regional share of global clinical trial country uses (annual)European Union202527%actual
Retail pharmacy prescription drug average annual growth (5-year)United States2021–20252.4%actual
Retail prescription drug volume compound annual growth rateUnited States2020–20252.4%actual
Retail share of medicine useUnited States202584%actual
Retail share of prescription medicine useUnited States202584%actual
Share of global pharmaceutical spending growth from top 15 countriesGlobal2025–203076%forecast
Share of medicine spending growthGlobal2025–203076%forecast
Small molecule share of Phase I trial startsGlobal202562%actual
Small molecule share of Phase I trial startsGlobal202562%actual
Small molecule share of Phase I trial startsGlobal202360%actual
Small molecule share of Phase I trial startsGlobal202360%actual
Small molecule share of Phase I trial startsGlobal201672%actual
Small molecule share of Phase I trial startsGlobal201672%actual
Tiered countries share of clinical trial country usesGlobal2021–202319%actual
Top 10 countries share of clinical trial country-usesGlobal2021–202358%actual
Top countries share of clinical trial pipeline useGlobal2021–202358%actual
Top countries share of medicine spending growthGlobal2026–203083%forecast
Total medicine usageGlobal20304 trillion defined daily dosesforecast
Unfilled prescription rate (all brands and branded generics)United Statesend of 202529%actual
Unfilled prescription rate across all brands and branded genericsUnited States202529%actual
Unfilled rate for novel medicine prescriptions (first year)United States2020–202465%actual

Cite & reuse

Cite this page

Data on this page is published under CC BY 4.0. Credit IQVIA Institute as the original publisher; each record page carries its own citation.

IQVIA Institute. Retrieved from StatOrigin: https://statorigin.org/sources/iqvia-institute

Keep exploring

Related

Last verified 17 September 2026. Link status is rechecked weekly.